Vanderbilt Ingram Cancer Center

Vanderbilt-Ingram Cancer Center (VICC) will host a special event for patients and families affected by neurofibromatosis (NF), a genetic disorder that can cause tumors in the nervous system. The Neurofibromatosis Patient and Family Symposium will be held Saturday, April 21, 9 a.m. – 1 p.m., at the VICC 8th floor conference center in the Preston Research Building, 2220 Pierce Ave.

Vanderbilt-Ingram Cancer Center (VICC) will host a special event for patients and families affected by neurofibromatosis (NF), a genetic disorder that can cause tumors in the nervous system.

Vanderbilt University Medical Center investigators have identified a growing number of serious and sometimes fatal cases of heart problems among cancer patients treated with some forms of immunotherapy.

Investigators at Vanderbilt-Ingram Cancer Center (VICC) and the Virginia Tech Carilion Research Institute (VTCRI) have revealed a gene mutation’s role in Von Hippel-Lindau syndrome, a genetically inherited disease which causes tumor growth in several organs.

Christine Lovly, MD, PhD, assistant professor of Medicine at Vanderbilt, has received a $200,000 grant to support promising new research on lung cancer.

James Allison, PhD, whose work led to the development of cancer immunotherapies known as “checkpoint inhibitors,” will deliver the next Flexner Discovery Lecture on Thursday, March 8.

Twenty-three volunteer leaders have been named to fill positions on three of Vanderbilt University Medical Center’s (VUMC) advisory boards and councils.